MedTrace Logo

Detecting EGFR T790M Mutations From Circulating Tumor Cells

NCT01734915 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2016-09-26

No results posted yet for this study

Summary

The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream. A device called the CTC-chip has been developed to find CTCs in the blood of patients with cancer. This is an experimental device. Using this device, the investigators will test participants' blood to try and find CTCs with the EGFR mutation and compare them with the results from the biopsy your doctor has recommended. The long-term goal of this research is to develop a way to test for the EGFR mutation that is less invasive than a tumor biopsy.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DEVICE

Circulating tumor cell chip

three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01734915 on ClinicalTrials.gov